Clinical Trial Update: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ARO-APOC3 in adults with Severe Hypertriglyceridemia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• ARO-APOC3 (APOC3 antisense oligonucleotide)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Severe Hypertriglyceridemia | Phase 2 | Status: COMPLETED | Results posted: 2026-03-24